Sort
39,280 grants matching “leukemia”
Development of selective Pin1 inhibitors to target a common oncogenic mechanism
$654,869Kun Ping Lu · Beth Israel Deaconess Medical Center · R01 · FY2018 · CA
Development of selective Pin1 inhibitors to target a common oncogenic mechanism
$654,869Gerburg M Wulf · Beth Israel Deaconess Medical Center · R01 · FY2021 · CA
Development of selective Pin1 inhibitors to target a common oncogenic mechanism
$654,869Gerburg M Wulf · Beth Israel Deaconess Medical Center · R01 · FY2020 · CA
Investigating the Role of VISTA in Driving Immune Evasion in Acute Myeloid Leukemia
$654,837Li Lily Wang · Cleveland Clinic Lerner Com-Cwru · R01 · FY2025 · CA
Center for Environment-Mediated Drug Resistance in Pediatric Cancer
$654,642Yves A Declerck · Children'S Hospital Of Los Angeles · U54 · FY2015 · CA
Identification of therapeutic targets for leukemia stem cells in AML-iPSC models
$654,506Eirini Papapetrou · Icahn School Of Medicine At Mount Sinai · R01 · FY2021 · CA
Discovery of First-in-class WDR5 PROTACs as a Novel Therapeutic Strategy for MLL-rearranged Leukemias
$654,354Jian Jin · Icahn School Of Medicine At Mount Sinai · R01 · FY2025 · CA
Hemopexin as an Early Biomarker of Anthracycline Cardiac Toxicity
$654,307Aarti Asnani · Beth Israel Deaconess Medical Center · R01 · FY2023 · HL
Signal Transduction by Tyrosine Phosphorylation
$654,096Tony R. Hunter · Salk Institute For Biological Studies · R01 · FY2019 · CA
NOVEL ANTITUMOR DISULFIDES
$654,041Prolx Pharmaceuticals, Lp · R44 · FY2002 · CA
Integration of germline and tumor genomes in CLL
$653,840Susan L Slager · Mayo Clinic Rochester · R01 · FY2019 · CA
Metabolic basis of B cell lineage leukemia relapse
$653,813Markus Mãschen · University Of California, San Francisco · R35 · FY2016 · CA
Tumor Heterogeneity and Acquired Resistance to EGFR Inhibition
$653,792Scott Kopetz · University Of Tx Md Anderson Can Ctr · R01 · FY2015 · CA
Therapeutic Elimination of Stem Cells for Relapsed Pediatric AML
$653,666Yang Liu · Children'S Research Institute · U01 · FY2014 · CA
Hematalogical Malignancies
$653,591Richard James Gilbertson · St. Jude Children'S Research Hospital · P30 · FY2014 · CA
Genomic Approaches to Aneuploidy
$653,449Roger H Reeves · Johns Hopkins University · R01 · FY2009 · HD
Project 1: Systematic discovery of cell-intrinsic mechanisms of cancer drug resistance
$653,390Scott R Manalis · Massachusetts Institute Of Technology · U54 · FY2017 · CA
Personalized vaccine for patients with AML
$653,338David E Avigan · Beth Israel Deaconess Medical Center · R01 · FY2022 · CA
Molecular screening: MALDI-TOF scanning of peptides(RMI)
$653,151University Of Chicago · R01 · FY2005 · HG
Transition State Analysis of Enzymatic Reactions
$653,028Vern L. Schramm · Albert Einstein College Of Medicine · R01 · FY2011 · GM
Dissecting innate immune signaling in pre-leukemia evolution
$652,991Daniel Starczynowski · Cincinnati Childrens Hosp Med Ctr · R01 · FY2022 · CA
A Molecular Approach to Dissecting MEK-Mediated Phosphorylation in Pediatric Leukemia
$652,805Karl A Scheidt · Northwestern University · R01 · FY2025 · CA
Development of Potent, Selective, Non-Myelotoxic FLT3 Inhibitors that Retain Efficacy Against Common Mechanisms of Resistance
$652,744Neil P Shah · University Of California, San Francisco · R01 · FY2025 · CA
MOUNT SINAI COMMUNITY CLINICAL ONCOLOGY PROGRAM
$652,654Rogerio C. Lilenbaum · Mount Sinai Medical Center (Miami Beach) · U10 · FY2008 · CA
Cell-Based HTS Campaign to Identify Negative Allosteric Modulators of the Leukemia-associated Tyrosine Kinase, BTKâ.
$652,558Paul A. Johnston · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · CA